The "Reducing Inflammation for Greater Health Trial (RIGHT)" Study-Concept, Rationale, and Design.

Sebastian E Sattui, Marnie Bertolet, Daniel E Forman, Michelle E Danielson, Shanshan Yao, Oscar L Lopez, Nancy W Glynn, Neelesh K Nadkarni, Akira Sekikawa, Tullia C Bruno, Toren Finkel, Anne B Newman

Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. · pubmed

Paper

Abstract

The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single-center, randomized, double-blind, placebo-controlled trial designed to test whether clazkizumab, an interleukin-6 (IL-6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo. The trial will enroll participants meeting the following inclusion criteria: (1) ≥ 70 years of age, (2) with low to moderate physical function, defined as self-reported difficulty walking 1/4 mile or climbing a flight of stairs, but able to walk 400 m at baseline exam, (3) usual walking speed between ≥ 0.44 and < 1.0 m/s on a 4-m walk or a body mass index of ≥ 28 kg/m

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The study aims to evaluate the efficacy of clazkizumab, an IL-6 inhibitor, in improving physical, cognitive, and vascular function in older adults. The trial addresses inflammation, which is a contributing factor to aging and age-related decline, making it relevant to longevity research.

Author of this paper? Send a correction.